Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment - Initiation Report
Climb Bio Inc. (NASDAQ: CLYM), a promising biotech company, focuses on enhancing autoimmune disease treatment. With Budoprutug and CLYM116, it's set to excel in 2025.